Advisor Group Inc. lifted its position in shares of AbbVie Inc (NYSE:ABBV) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 186,522 shares of the company’s stock after buying an additional 5,053 shares during the period. Advisor Group Inc.’s holdings in AbbVie were worth $16,577,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of ABBV. Iberiabank Corp boosted its position in AbbVie by 1.2% during the second quarter. Iberiabank Corp now owns 81,633 shares of the company’s stock valued at $5,919,000 after purchasing an additional 934 shares during the last quarter. Lawson Kroeker Investment Management Inc. NE boosted its position in AbbVie by 2.4% during the second quarter. Lawson Kroeker Investment Management Inc. NE now owns 4,546 shares of the company’s stock valued at $330,000 after purchasing an additional 106 shares during the last quarter. Waverton Investment Management Ltd boosted its position in AbbVie by 2.8% during the second quarter. Waverton Investment Management Ltd now owns 10,455 shares of the company’s stock valued at $758,000 after purchasing an additional 286 shares during the last quarter. Private Trust Co. NA boosted its position in AbbVie by 6.4% during the second quarter. Private Trust Co. NA now owns 86,540 shares of the company’s stock valued at $6,274,000 after purchasing an additional 5,219 shares during the last quarter. Finally, Capital Investment Advisors LLC boosted its position in AbbVie by 3.5% during the second quarter. Capital Investment Advisors LLC now owns 25,330 shares of the company’s stock valued at $1,837,000 after purchasing an additional 868 shares during the last quarter. 69.19% of the stock is owned by institutional investors.
In other news, insider Henry O. Gosebruch sold 18,300 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now owns 81,287 shares in the company, valued at $7,360,537.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares in the company, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. Insiders sold 494,676 shares of company stock worth $47,237,938 in the last 90 days. Corporate insiders own 0.23% of the company’s stock.
Shares of AbbVie Inc (NYSE ABBV) opened at $104.64 on Monday. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. The stock has a market capitalization of $166,810.00, a P/E ratio of 25.40, a price-to-earnings-growth ratio of 1.22 and a beta of 1.53. AbbVie Inc has a 52 week low of $59.27 and a 52 week high of $104.87.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.02. The firm had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.21 earnings per share. equities research analysts forecast that AbbVie Inc will post 5.56 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a $0.71 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date is Thursday, January 11th. This represents a $2.84 annualized dividend and a yield of 2.71%. AbbVie’s dividend payout ratio is currently 68.93%.
Several research analysts recently commented on the company. UBS Group reissued a “neutral” rating on shares of AbbVie in a research report on Friday, October 13th. Jefferies Group increased their price target on AbbVie from $107.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, October 16th. BMO Capital Markets reissued a “hold” rating and set a $84.00 price target on shares of AbbVie in a research report on Tuesday, November 21st. Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $115.00 price target for the company in a research report on Thursday. Finally, Piper Jaffray Companies increased their price target on AbbVie to $115.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. AbbVie presently has a consensus rating of “Buy” and a consensus price target of $101.38.
TRADEMARK VIOLATION NOTICE: “Advisor Group Inc. Purchases 5,053 Shares of AbbVie Inc (ABBV)” was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.truebluetribune.com/2018/01/22/advisor-group-inc-purchases-5053-shares-of-abbvie-inc-abbv.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.